Taylor & Francis Group
Browse
kadi_a_2102116_sm2370.docx (545.98 kB)

ESR2 expression in subcutaneous adipose tissue is related to body fat distribution in women, and knockdown impairs preadipocyte differentiation

Download (545.98 kB)
journal contribution
posted on 2022-07-20, 12:00 authored by Fozia Ahmed, Susanne Hetty, Milica Vranic, Giovanni Fanni, Joel Kullberg, Maria João Pereira, Jan W Eriksson

Oestrogen receptor 2 (ESR2) expression has been shown to be higher in subcutaneous adipose tissue (SAT) from postmenopausal compared to premenopausal women. The functional significance of altered ESR2 expression is not fully known. This study investigates the role of ESR2 for adipose tissue lipid and glucose metabolism. SAT biopsies were obtained from 44 female subjects with or without T2D. Gene expression of ESR2 and markers of adipose function and metabolism was assessed. ESR2 knockdown was performed using CRISPR/Cas9 in preadipocytes isolated from SAT of females, and differentiation rate, lipid storage, and glucose uptake were measured.

ESR2 expression was inversely correlated with measures of central obesity and expression of some fatty acid oxidation markers, and positively correlated with lipid storage and glucose transport markers. Differentiation was reduced in ESR2 knockdown preadipocytes. This corresponded to reduced expression of markers of differentiation and lipogenesis. Glucose uptake was reduced in knockdown adipocytes.

Our results indicate that ESR2 deficiency in women is associated with visceral adiposity and impaired subcutaneous adipocyte differentiation as well as glucose and lipid utilization. High ESR2 expression, as seen after menopause, could be a contributing factor to SAT expansion. This may support a possible target to promote a healthy obesity phenotype.

Funding

This work was supported by research grants from the Swedish Diabetes Foundation DIA2021-661, European Commision via the Marie Sklodowska Curie Innovative Training Network TREATMENT (H2020-MSCA-ITN-721236), EXODIAB, the Family Ernfors Foundation, the P.O Zetterling Foundation, the Swedish Society for Medical Research, AstraZeneca R&D, Novo Nordisk Foundation NNF20OC0063864, the Rudberg Agnes and Mac Foundation, and the Uppsala University Hospital ALF grants.

History